Phathom Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: Heidi Kunz

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Heidi Kunz”): 34,023,182 for, 451,384 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class III Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class III directors for a three-year term expiring at the Company's 20…”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 7,314,444 for, 45,590 withheld.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Description as filed by funds: To elect two class II directors to hold office until the 2026 Annual Meeting of Stockholders: James Topper, M.D., Ph.D.

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: James Topper, M.D., Ph.D.”): 26,884,171 for, 7,590,395 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class III Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class III directors for a three-year term expiring at the Company's 20…”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 3,972,370 for, 3,387,664 withheld.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

The 15 asset managers below reported 1,307,519 for, 668,534 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").

Phathom Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers”): 24,584,781 for, 8,704,739 against, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 42 managers: 2,895,047 for, 4,464,987 against, 681,935 abstained. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers ("say-on-frequency").

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 40 managers: 7,358,290 1 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 105 managers: 11,784 for, 20 against, 240 abstained, 500 not voted, 38,497,110 1 year, 2,495,309 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

Phathom Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 51,670,346 for, 177,785 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2025:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 8,041,969 for.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.